Regenstrief Institute and Boomerang Ventures are announcing a partnership to develop and disseminate healthcare solutions to improve the wellbeing of people around the world. The new partnership will enable Regenstrief to expand the reach of its innovations, and Boomerang Ventures will benefit from the expertise of the institute’s research scientists.
Regenstrief Institute is a global leader dedicated to improving health and healthcare through innovations and research in biomedical informatics, health services and aging. Boomerang Ventures is a venture fund and studio that works to build, launch and fund new companies and concepts to help improve healthcare. Together, they will work to develop and commercialize innovations from Regenstrief research scientists, making them more widely available and more impactful.
By engaging Regenstrief scientists early in the research process to assist them in building and scaling healthcare solutions beyond the grant funding cycle, Boomerang Ventures can help navigate risks and regulations and build relationships with other partners to create a successful and innovative ecosystem.
“Bringing even well thought out, evidence-backed concepts to market can be complex. With its depth and expertise, Boomerang Ventures will help us take the discoveries made in our research to the next stage, refining and connecting these promising concepts to professionals and markets to help them flourish,” said Todd Saxton, PhD, Regenstrief vice president for business development. “It is one promising approach in an array of ways to move from research to impact. We look forward to working closely with Boomerang Ventures to advance our research for the betterment of people’s health and healthcare systems.”
Boomerang Ventures will rely on the expertise, experience and knowledge of Regenstrief experts in other ventures as well.
“Regenstrief and its scientists are well known for their rigorous research, analysis and evaluation,” said Oscar Moralez, managing partner, Boomerang Ventures. “We look forward to this partnership as we work to guide the implementation of these healthcare innovations. This partnership will help bridge the gap between research and the business world by combining Regenstrief’s tremendous talent with the expertise, collaboration and other resources we can contribute to scale healthcare-revolutionizing products into the marketplace.”
About Regenstrief Institute
Founded in 1969 in Indianapolis, the Regenstrief Institute is a local, national and global leader dedicated to a world where better information empowers people to end disease and realize true health. A key research partner to Indiana University, Regenstrief and its research scientists are responsible for a growing number of major healthcare innovations and studies. Examples range from the development of global health information technology standards that enable the use and interoperability of electronic health records to improving patient-physician communications, to creating models of care that inform practice and improve the lives of patients around the globe.
Sam Regenstrief, a nationally successful entrepreneur from Connersville, Indiana, founded the institute with the goal of making healthcare more efficient and accessible for everyone. His vision continues to guide the institute’s research mission.
About Boomerang Ventures
Boomerang Ventures is on a mission to help solve the most pressing healthcare challenges facing the world today through its venture fund and studio and thus ensure a better quality of life for all. It works to build, launch, and fund new healthcare and life sciences companies with the potential to disrupt legacy technologies and processes and in so doing improve patient outcomes and lower the cost of health care.
A diverse team of successful founders and entrepreneurs serve as Boomerang Studio advisors, mentors, strategists, and guides to new founders and entrepreneurs as well as to sponsoring corporations, universities, health systems and related entities to identify and execute best path forward launch strategies.